Association of lung immune prognostic index (LIPI) with survival of first line immune checkpoint inhibitors single agent or in combination with chemotherapy in untreated advanced NSCLC patients

Blanc-Durand, F.;Auclin, E.;Planchard, D.;Aix, S. Ponce;Mezquita, L.;et.al.
(2019) ESMO Immuno-Oncology Congress 2019 — Location: (Switzerland) Geneva (11.December.2019)

Files

2019_Blanc-Durand_Ann_Oncol_17P.pdf
  • Open Access
  • Adobe PDF
  • 61.76 KB
Download

Details

Authors
  • Blanc-Durand, F.
    Author
  • Auclin, E.
    Author
  • Planchard, D.
    Author
  • Aix, S. Ponce
    Author
  • Aboubakar Nana, FrankUCLouvain
    Author
  • Mezquita, L.
    Author
Show more
Abstract
BACKGROUND : The Lung Immune Prognostic Index (LIPI), combining the derived neutrophils/[leucocytes minus neutrophils] ratio (dNLR) and lactate dehydrogenase (LDH), has been associated with survival for ICI-single agent in large cohorts of refractory advanced NSCLC. However the role of LIPI in untreated NSCLC patients has not been explored yet. We assessed the value of LIPI in the front-line setting of advanced NSCLC patients (pts) treated with ICI-single agent or in combination with chemotherapy and compared to a cohort of pts treated exclusively with chemotherapy (CT). [...]
Affiliations

Citations

  • APA
  • Chicago
  • FWB

Blanc-Durand, F., Auclin, E., Planchard, D., Aix, S. P., Hendriks, L., Sullivan, I. G., Saravia, D., Routy, B., Castro, R. L., Pilotto, S., Aboubakar Nana, F., Kassouf, E., Rodriguez, A., Martin, A. A., Bluthgen, M. V., Duchemann, B., Caramella, C., Nadal, E., Besse, B., & Mezquita, L. (2019). Association of lung immune prognostic index (LIPI) with survival of first line immune checkpoint inhibitors single agent or in combination with chemotherapy in untreated advanced NSCLC patients. Annals of Oncology, 30(Suppl 11), xi5. https://doi.org/10.1093/annonc/mdz447.015 (Original work published 2019)